Login
Cell Therapies, Cancer & Rare Diseases
- Pininvest Analysis
Cell therapies have opened new treatment fields by cell inhibitors, gene modification, or even gene replacement
By gene modification after extraction of white blood cells from a leukemia-fighting patient, the cells are bolstered for more vigorous attack of cancer cells and reinjected in the patient; the Novartis treatment researched by University of Pennsylvania has been approved by the FDA in August ’17 and more than 76 applications have been accepted for testing in this promising field, possibly extending the procedure to some forms of brain and lung cancer patients - Check our note "Immunotherapy by adaptive cell transfer (ACT)' for more information
Gene replacement aims disease caused by a single faulty gene and the first treatment, targeting vision loss due to genetic mutation, introduced by Spark Therapeutics, is the first of its kind to be approved by FDA (December ’17)
Cell Therapies, Cancer & Rare Diseases • Updated:
| Name | Ticker | Exchange | Sector | Industry | Currency | Cur.Price | Mkt.Cap | Perf. | Momentum | Vol. | Risk Contrib. | MDD |
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | ADAP | NASDAQ | Health Care | Biopharmaceuticals | USD | 5.04 | 782 M | 52.7% | Neutral | 118% | 5% | -67% |
|
|
| Amgen | AMGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 249.62 | 145 B | 14.7% | Weak Up | 26% | 1% | -16% |
|
|
| Bellicum Pharmaceuticals | BLCM | NASDAQ | Health Care | Biopharmaceuticals | USD | 3.51 | 18 M | -44.7% | Sharp Down | 107% | 5% | -70% |
|
|
| bluebird bio, Inc. | BLUE | NASDAQ | Health Care | Biopharmaceuticals | USD | 29.54 | 2.0 B | -37.6% | Sharp Down | 74% | 3% | -64% |
|
|
| Cellectis (ADR) | CLLS | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 19.51 | 829 M | 79.2% | Sharp Down | 88% | 6% | -45% |
|
|
| Celyad (ADR) | CYAD | NASDAQ | Health Care | Biopharmaceuticals | USD | 6.95 | 97 M | -22.8% | Weak Down | 57% | 1% | -45% |
|
|
| Clovis Oncology, Inc. | CLVS | NASDAQ | Health Care | Biopharmaceuticals | USD | 6.25 | 552 M | -13.3% | Neutral | 96% | 5% | -57% |
|
|
| Corvus Pharmaceuticals | CRVS | NASDAQ | Health Care | Biopharmaceuticals | USD | 2.83 | 79 M | 21.5% | Sharp Down | 101% | 4% | -49% |
|
|
| CRISPR Therapeutics | CRSP | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 123.11 | 8.7 B | 155.8% | Sharp Down | 64% | 5% | -47% |
|
|
| Editas Medicine | EDIT | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 41.53 | 2.6 B | 84.3% | Sharp Down | 86% | 6% | -56% |
|
|
| Gilead Sciences | GILD | NASDAQ | Health Care | Biopharmaceuticals | USD | 65.30 | 82 B | -8.8% | Neutral | 28% | 1% | -30% |
|
|
| Immunogen | IMGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 7.62 | 1.4 B | 122.2% | Weak Down | 75% | 4% | -32% |
|
|
| Intellia Therapeutics | NTLA | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 76.35 | 4.5 B | 493.7% | Weak Up | 87% | 7% | -44% |
|
|
| Intercept Pharmaceuticals | ICPT | NASDAQ | Health Care | Biopharmaceuticals | USD | 21.41 | 706 M | -70.2% | Neutral | 88% | 4% | -79% |
|
|
| Invitae | NVTA | NYSE | Health Care | Gene Editing - Cell Therapies | USD | 39.07 | 6.9 B | 188.1% | Sharp Down | 83% | 5% | -42% |
|
|
| MacroGenics | MGNX | NASDAQ | Health Care | Biopharmaceuticals | USD | 31.28 | 1.8 B | 464.6% | Strong Up | 141% | 5% | -40% |
|
|
| NantKwest, Inc. | NK | NASDAQ | Health Care | Biopharmaceuticals | USD | 32.49 | 3.5 B | 887.5% | Neutral | 124% | 7% | -39% |
|
|
| Neos Therapeutics | NEOS | NASDAQ | Health Care | Drug Manufacturers -Specialty Pharma | USD | 1.15 | 57 M | 21.1% | Weak Up | 100% | 3% | -53% |
|
|
| Novartis (ADR) | NVS | NYSE | Health Care | Drug Manufacturers - Diversified | USD | 86.75 | 196 B | 5.3% | Neutral | 20% | 1% | -14% |
|
|
| Regeneron Pharmaceuticals | REGN | NASDAQ | Health Care | Biopharmaceuticals | USD | 481.16 | 51 B | -6.0% | Neutral | 35% | 1% | -32% |
|
|
| REGENXBIO | RGNX | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 35.34 | 1.3 B | 10.6% | Sharp Down | 58% | 4% | -39% |
|
|
| Sangamo Therapeutics | SGMO | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 11.64 | 1.6 B | 59.9% | Neutral | 80% | 5% | -40% |
|
|
| uniQure | QURE | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 34.88 | 1.6 B | -33.5% | Neutral | 59% | 3% | -57% |
|
|
| Vericel | VCEL | NASDAQ | Health Care | Gene Editing - Cell Therapies | USD | 57.06 | 2.6 B | 415.4% | Strong Up | 54% | 3% | -21% |
|
|
| ZIOPHARM Oncology | ZIOP | NASDAQ | Health Care | Biopharmaceuticals | USD | 3.45 | 739 M | 27.3% | Sharp Down | 81% | 5% | -42% |
|